Investor Presentaiton slide image

Investor Presentaiton

Daiichi-Sankyo Adverse Events of Special Interest Dato-DXd N=297 Docetaxel N=290 AESI, n (%) Stomatitis/oral mucositisa All grades 160 (54) 59 (20) Grade ≥3 19 (6) 4 (1) Ocular eventsb All grades 57 (19) 27 (9) Grade ≥3 5 (2)c 0 Adjudicated drug-related ILDd 25 (8) 12 (4) All grades Grade ≥3 Grade 5 10 (3) 7 (2) 4 (1) 1 (0.3) • Stomatitis/oral mucositis associated with Dato-DXd resulted in a low rate of discontinuation (0.7%) Dry eye was the most common ocular event seen with Dato-DXd (6.1%; primarily grade ≤2), followed by increased lacrimation (5.4%) Seven adjudicated drug-related grade 5 ILD events • • Primary cause of death in 4 out of 7 was attributed to disease progression by investigator Non-squamous: 4 of 232 patients (1.7%); Squamous: 3 of 65 patients (4.6%)e IRRs were observed in 24 patients (8%) with either Dato-DXd or docetaxel; all were grade ≤2 with the exception of 1 grade 3 event AESI, adverse event of special interest; ILD, interstitial lung disease; IRR, infusion-related reaction; MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; SMQ, standardized MedDRA query; SOC, system organ class. AESIs listed in this slide are treatment emergent and include all PTs that define the medical concept. *Events included the selected PTs oral mucositis/stomatitis, oropharyngeal pain, mouth ulceration, odynophagia, dysphagia, oral pain, glossitis, pharyngeal inflammation, aphthous ulcer, and oral mucosa erosion. "Ocular events included selected PTs from the corneal disorder SMQ and selected relevant PTs from the eye disorder SOC. "Included 4 cases of keratitis and 1 case of ulcerative keratitis. "ILD includes events that were adjudicated as ILD and related to use of Dato-DXd or docetaxel (includes cases of potential ILD/pneumonitis based on MedDRA v26.0 for the narrow ILD SMQ, selected terms from the broad ILD SMQ, and PTs of respiratory failure and acute respiratory failure). *Among treated patients, histology information per the case report form. 15
View entire presentation